Progyny (PGNY) Set to Announce Earnings on Thursday

Progyny (NASDAQ:PGNY) is set to post its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Progyny to post earnings of $0.14 per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Progyny (NASDAQ:PGNY) last announced its earnings results on Tuesday, February 27th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.04. Progyny had a net margin of 5.70% and a return on equity of 12.64%. The business had revenue of $269.94 million for the quarter, compared to the consensus estimate of $274.08 million. During the same quarter in the prior year, the firm posted $0.03 earnings per share. The business’s revenue for the quarter was up 26.0% on a year-over-year basis. On average, analysts expect Progyny to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Progyny Trading Up 2.0 %

Shares of PGNY opened at $33.06 on Wednesday. Progyny has a twelve month low of $29.44 and a twelve month high of $44.95. The company has a market cap of $3.18 billion, a P/E ratio of 53.32, a P/E/G ratio of 1.31 and a beta of 1.51. The company’s fifty day simple moving average is $34.95 and its 200-day simple moving average is $35.62.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Leerink Partnrs reissued an “outperform” rating on shares of Progyny in a research note on Monday, February 26th. Truist Financial reaffirmed a “buy” rating and issued a $46.00 price target on shares of Progyny in a research note on Wednesday, April 17th. KeyCorp reduced their price target on shares of Progyny from $45.00 to $43.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 28th. SVB Leerink initiated coverage on shares of Progyny in a research note on Monday, February 26th. They issued an “outperform” rating and a $49.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $48.00 price target on shares of Progyny in a research note on Wednesday, February 28th. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $48.30.

Insider Activity

In other news, President Michael E. Sturmer sold 6,395 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $37.60, for a total value of $240,452.00. Following the sale, the president now directly owns 384,553 shares in the company, valued at approximately $14,459,192.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, President Michael E. Sturmer sold 6,395 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $37.60, for a total value of $240,452.00. Following the sale, the president now directly owns 384,553 shares in the company, valued at approximately $14,459,192.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman David J. Schlanger sold 71,272 shares of the firm’s stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $37.80, for a total transaction of $2,694,081.60. Following the completion of the sale, the chairman now owns 86,312 shares in the company, valued at $3,262,593.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 102,770 shares of company stock worth $3,853,985. Corporate insiders own 12.30% of the company’s stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.